Open an account

Foghorn Therapeutics

FHTX · NASDAQ

$2.01+$0.14 (+7.49%)TodayMarket closed ·
Prev close $1.87

About FHTX

Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 106 full-time employees. The company went IPO on 2020-10-23. The firm is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control platform, it is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The firm is also developing multiple product candidates in oncology. The Gene Traffic Control platform provides an integrated and mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing to identify, validate and potentially drug targets within this system. Its platform enables to produce components of the chromatin regulatory system at scale, thereby allowing to identify these genetic dependencies, understand their mechanism and target their vulnerabilities.

Employees
106
Headquarters
Cambridge, Massachusetts
Listed
Oct 23, 2020
Sector
Health Care
Industry
Biotechnology
Website
foghorntx.com

FHTX key statistics

Market cap
119.36M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.46M
Volume
555.10K
Open price
$1.87
High today
$2.07
Low today
$1.87
52 Week high
$7.61
52 Week low
$1.79

Foghorn Therapeutics (FHTX) at a glance

As of Oct 20, 2026, Foghorn Therapeutics (FHTX) shares are priced at $2.01, giving the company a market cap of 119.36M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.87 and $2.07. The current price is 7.5% above the day's low and 2.7% below its high.

Volume so far is 555.10K shares, below the average of 1.46M shares a day.

Over the past year Foghorn Therapeutics has ranged from $1.79 to $7.61, and now sits 4% of the way up that range.

Foghorn Therapeutics met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported -$0.10 per share against an estimate of -$0.261.

The average analyst price target is $10.09, 401.8% above the current price, from 7 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

57%of 7 analyst ratings say Buy
  • Buy57.1%
  • Hold42.9%
  • Sell0.0%
Price target · 11 analystsAvg $10.09
Low
$5.05
Now
$2.01
High
$14.70

FHTX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 24.8% on average.

  1. Q3 FY24: reported -$0.31 per share against an estimate of -$0.4492
  2. Q4 FY24: reported -$0.30 per share against an estimate of -$0.3337
  3. Q1 FY25: reported -$0.30 per share against an estimate of -$0.349
  4. Q2 FY25: reported -$0.28 per share against an estimate of -$0.3657
  5. Q3 FY25: reported -$0.25 per share against an estimate of -$0.3395
  6. Q4 FY25: reported -$0.34 per share against an estimate of -$0.2523
  7. Q1 FY26: reported -$0.29 per share against an estimate of -$0.3111
  8. Q2 FY26: reported -$0.10 per share against an estimate of -$0.261

FHTX news

  • Press releaseBusiness Wire

    FHTX Investors with $100,000 in Losses Have Opportunity to Join Foghorn Therapeutics Inc. Fraud Investigation with SBS Law

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX

  • Avi Kapoor

    Nasdaq Gains 100 Points; ISM manufacturing PMI Slips In September

  • Vandana Singh

    Foghorn Therapeutics Pivots Pipeline after Ending Eli Lilly Deal

  • Avi Kapoor

    Dow Falls Over 200 Points; Micron Earnings Top Views

  • Press releaseGlobe Newswire

    Next-Generation DNA Repair Therapies Open New Frontiers in Oncology

  • 12 Health Care Stocks Moving In Friday's After-Market Session

Similar companies

Companies in the same industry as Foghorn Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.